The Future of Neoadjuvant Immunotherapy in MIBC
Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Critical Unmet Needs for Patients with MIBC
Terence Friedlander, MD, summarizes the remaining unmet needs for patients with MIBC.
Factors for Consideration when Choosing an Adjuvant Therapy Regimen for Patients with MIBC
Dr Terence Friedlander explains which adjuvant therapy he would have recommended for the patient with MIBC from the presented case.
CheckMate 274: Data Updates in MIBC from GU ASCO, ASCO, and ESMO 2022
Terence Friedlander, MD, continues his discussion of the CheckMate 247 trial by highlighting important updates from recent conferences on adjuvant nivolumab therapy in patients with MIBC.
Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Available Adjuvant Therapy Options for Patients with Stage II or III MIBC after Cystectomy
Terence Friedlander, MD, reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.
Eligibility for Cisplatin Therapy in Patients with MIBC
Dr Terence Friedlander defines cisplatin eligibility in patients with MIBC and discusses how many patients receive neoadjuvant cisplatin and the treatment approaches if a patient is ineligible.
Case Presentation: A 75-Year-Old Woman with Muscle-Invasive Bladder Cancer (MIBC)
Terence Friedlander, MD, presents the case of a 75-year-old patient with stage IIIA muscle-invasive bladder cancer (MIBC) for review, and explains how patients are risk-stratified.
2 Commerce Drive Cranbury, NJ 08512